Tempus AI shares rise following executive order promoting AI to produce solutions for pediatric cancer
Shares of AI medical diagnostics company Tempus AI have shot up over 5% today. The stock is up over 150% for the year.
Yesterday, President Trump signed an executive order to boost the use of AI to “produce meaningful solutions to pediatric, adolescent, and young adulthood cancer,” which may be fueling the stock’s rise.
Last week, the company announced FDA approval of its Tempus xR IVD device, an RNA sequencing tool that allows doctors to tailor therapies for cancer patients.